Roche's Polivy ADC Is Approved As Another New Option For R/R DLBCL
The first-in-class anti-CD79b antibody-drug conjugate received a swift accelerated approval by the US FDA based on the results of a Phase Ib/II trial, for the same setting as CAR-T agents.
You may also be interested in...
Pyxis says its three preclinical ADCs, acquired from Pfizer and LegoChem, offer immunomodulatory effects as well as direct killing of tumor cells. It hopes all three will reach Phase I in 2022.
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.